IN2012DN02876A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02876A
IN2012DN02876A IN2876DEN2012A IN2012DN02876A IN 2012DN02876 A IN2012DN02876 A IN 2012DN02876A IN 2876DEN2012 A IN2876DEN2012 A IN 2876DEN2012A IN 2012DN02876 A IN2012DN02876 A IN 2012DN02876A
Authority
IN
India
Prior art keywords
compounds
coupled receptor
protein coupled
modulate
modulating
Prior art date
Application number
Inventor
Yingzhi Bi
Carolyn Diane Dzierba
Joanne J Bronson
Kenneth Carson
Giovanni Cianchetta
Li Dong
Cynthia Fink
Michael Green
David Kimball
John E Macor
Soojin Kwon
Jiancheng Wang
Yulian Zhang
Greg Zipp
Original Assignee
Bristol Myers Squibb Co
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Lexicon Pharmaceuticals Inc filed Critical Bristol Myers Squibb Co
Publication of IN2012DN02876A publication Critical patent/IN2012DN02876A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
IN2876DEN2012 2009-10-07 2010-10-06 IN2012DN02876A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24946509P 2009-10-07 2009-10-07
PCT/US2010/051572 WO2011044195A1 (en) 2009-10-07 2010-10-06 Modulators of g protein-coupled receptor 88

Publications (1)

Publication Number Publication Date
IN2012DN02876A true IN2012DN02876A (en) 2015-07-24

Family

ID=43480829

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2876DEN2012 IN2012DN02876A (en) 2009-10-07 2010-10-06

Country Status (7)

Country Link
US (1) US8497271B2 (en)
EP (1) EP2486030B1 (en)
JP (1) JP2013507369A (en)
CN (1) CN102686575A (en)
ES (1) ES2428492T3 (en)
IN (1) IN2012DN02876A (en)
WO (1) WO2011044195A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8598213B2 (en) 2011-07-08 2013-12-03 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
UA111746C2 (en) * 2011-07-08 2016-06-10 Х. Луннбек А/С POSITIVE Allosteric Modulators of the Nicotinic Acetylcholine Receptor
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
WO2014006117A1 (en) * 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
HK1216095A1 (en) * 2012-12-10 2016-10-14 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN113005089A (en) * 2019-12-20 2021-06-22 泰州医药城国科化物生物医药科技有限公司 Cell screening model of unlabeled cell membrane receptor GPR88 and application
CN111592531B (en) * 2020-06-23 2023-08-15 上海鲲博玖瑞医药科技发展有限公司 Preparation method of forbestine
GB202209195D0 (en) 2022-06-22 2022-08-10 Pandeia Therapeutics Ltd Modulators of g protein-coupled receptor 88
GB202209193D0 (en) 2022-06-22 2022-08-10 Pandeia Therapeutics Ltd Modulators of g protein-coupled receptor 88
WO2026055419A1 (en) 2024-09-05 2026-03-12 Acadia Pharmaceuticals Inc. Modulators of g protein-coupled receptor 88

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9307570A (en) 1992-12-02 1999-05-25 Pfizer Catechol ethers as selective pdeiv inhibitors
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6172091B1 (en) * 1998-10-14 2001-01-09 Ortho-Mcneil Pharmaceutical, Inc. 1,2-Disubstituted cyclopropanes
CA2477692A1 (en) 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
AU2003295781A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
CA2601508C (en) * 2005-03-17 2012-01-03 Pfizer, Inc. Cyclopropanecarboxamide derivatives
CN100494167C (en) 2005-08-02 2009-06-03 天津大学 Anti-hepatitis B virus tertiary amine oxide, preparation method and application of preparation medicine
JP2007217408A (en) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd Pharmaceutical composition
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
WO2008022155A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88

Also Published As

Publication number Publication date
EP2486030A1 (en) 2012-08-15
WO2011044195A1 (en) 2011-04-14
EP2486030B1 (en) 2013-07-24
US8497271B2 (en) 2013-07-30
US20110245264A1 (en) 2011-10-06
CN102686575A (en) 2012-09-19
JP2013507369A (en) 2013-03-04
ES2428492T3 (en) 2013-11-08

Similar Documents

Publication Publication Date Title
NZ612380A (en) Modulators of toll-like receptors
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
MY172156A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12016501389A1 (en) S1p modulating agent
AU2011232516A8 (en) Chemical compounds
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
IN2012DN02580A (en)
MX2011008602A (en) Methods of treating hair related conditions.
ZA201100014B (en) Piperazine derivatives used as cav2.2 calcium channel modulators
UA107476C2 (en) Pharmaceutical substance on the basis of mitochondrially addressed compounds
MX2009007336A (en) 5-furopyridinone substituted indazoles.
WO2010057088A3 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
TN2013000201A1 (en) Methods and compositions for drying coal
MX2009010903A (en) Methods of preparing imidazole-based compounds.
MY151180A (en) Electrocoating composition comprising a crater control additive
WO2009154739A3 (en) Smoothened receptor modulators
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
PH12013500819A1 (en) Tidal flow modulator
WO2010060070A3 (en) Indolinone modulators of dopamine receptor
PH12014500934A1 (en) Nicotinic receptor non-competitive modulators
UA101624C2 (en) Pyrrolidine-2-one derivatives as androgen receptor modulators
UA49630U (en) Composition of surface active substance for the formation of wear-resistant coatings
UA74358U (en) Phytotea composition
UA97521C2 (en) I-rna-agent modulating downregulation of alpha-enac expression